These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 29155123)

  • 1. Baseline factors associated with better response to insulin lispro low mixture or insulin glargine: A post hoc analysis of the DURABLE study.
    Jia N; Kindracki Z; Rodriguez A
    Diabetes Res Clin Pract; 2018 Jan; 135():134-142. PubMed ID: 29155123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post-hoc analysis of the AWARD-4 study across baseline body mass index subgroups.
    Fuechtenbusch M; Aberle J; Heitmann E; Nicolay C; Jung H
    Diabetes Obes Metab; 2019 Jun; 21(6):1340-1348. PubMed ID: 30737891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of insulin intensification strategies with insulin lispro low mixture twice daily versus basal insulin glargine and prandial insulin lispro once daily in East Asian and Caucasian patients with type 2 diabetes mellitus.
    Jeong IK; Chung CH; Zhou Z; Han JH; Duan R; Edralin DM; Rodriguez A
    J Diabetes; 2017 Apr; 9(4):396-404. PubMed ID: 27171584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of a premixed versus a basal-plus insulin regimen as intensification for type 2 diabetes by timing of the main meal.
    Gross JL; Rojas A; Shah S; Tinahones FJ; Cleall S; Rodríguez A
    Curr Med Res Opin; 2016 Jun; 32(6):1109-16. PubMed ID: 26934128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Insulin Treatment with Glargine or Premixed Insulin Lispro Programs in Type 2 Diabetes Mellitus Patients: A Meta-analysis of Randomized Clinical Trials.
    Sun D; Zhang X; Hou XX
    Diabetes Technol Ther; 2018 Sep; 20(9):622-627. PubMed ID: 30095984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with reaching or not reaching target HbA
    Scheen AJ; Schmitt H; Jiang HH; Ivanyi T
    Diabetes Metab; 2017 Feb; 43(1):69-78. PubMed ID: 27988180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study.
    Derwahl KM; Bailey TS; Wernicke-Panten K; Ping L; Pierre S
    Diabetes Technol Ther; 2018 Jan; 20(1):49-58. PubMed ID: 29232162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Starting an insulin regimen with insulin lispro mix 25 versus glargine insulin for type 2 diabetes].
    Fernández Landó L; Massari F; Oviedo A; Jiang H
    Medicina (B Aires); 2012; 72(3):235-42. PubMed ID: 22763161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study.
    Bowering K; Reed VA; Felicio JS; Landry J; Ji L; Oliveira J
    Diabet Med; 2012 Sep; 29(9):e263-72. PubMed ID: 22672081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycaemic responses in Asian and non-Asian people with type 2 diabetes initiating insulin glargine 100 units/mL: A patient-level pooled analysis of 16 randomised controlled trials.
    Chan JCN; Bunnag P; Chan SP; Tan ITI; Tsai ST; Gao L; Landgraf W
    Diabetes Res Clin Pract; 2018 Jan; 135():199-205. PubMed ID: 29179974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8.
    Harris C; Forst T; Heise T; Plum-Mörschel L; Watkins E; Zhang Q; Fan L; Garhyan P; Porksen N
    Diabetes Technol Ther; 2017 Aug; 19(8):463-470. PubMed ID: 28817342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding heterogeneity in response to antidiabetes treatment: a post hoc analysis using SIDES, a subgroup identification algorithm.
    Hardin DS; Rohwer RD; Curtis BH; Zagar A; Chen L; Boye KS; Jiang HH; Lipkovich IA
    J Diabetes Sci Technol; 2013 Mar; 7(2):420-30. PubMed ID: 23567001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial.
    Bolli GB; Riddle MC; Bergenstal RM; Wardecki M; Goyeau H; Home PD;
    Diabetes Metab; 2017 Sep; 43(4):351-358. PubMed ID: 28622950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes.
    Orchard TJ; Cariou B; Connelly MA; Otvos JD; Zhang S; Antalis CJ; Ivanyi T; Hoogwerf BJ
    Cardiovasc Diabetol; 2017 Jun; 16(1):73. PubMed ID: 28587667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of basal supported oral therapy with insulin glargine, in Japanese insulin-naive, type 2 diabetes patients, with or without microvascular complications: subanalysis of the observational, non-interventional, 24-week follow-up Add-on Lantus® to Oral Hypoglycemic Agents (ALOHA) study.
    Odawara M; Kadowaki T; Naito Y
    J Diabetes Complications; 2015; 29(1):127-33. PubMed ID: 25449981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Observational Registry of Basal Insulin Treatment in Patients with Type 2 Diabetes in China: Safety and Hypoglycemia Predictors.
    Zhang T; Ji L; Gao Y; Zhang P; Zhu D; Li X; Ji J; Zhao F; Zhang H; Guo X
    Diabetes Technol Ther; 2017 Nov; 19(11):675-684. PubMed ID: 29090977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The DURABLE trial study design: comparing the safety, efficacy, and durability of insulin glargine to insulin lispro mix 75/25 added to oral antihyperglycemic agents in patients with type 2 diabetes.
    Fahrbach J; Jacober S; Jiang H; Martin S
    J Diabetes Sci Technol; 2008 Sep; 2(5):831-8. PubMed ID: 19885269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
    Zhang T; Lin M; Li W; Fan X; Du T; Zhao Y; Zhang X
    Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.